高级搜索

恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床观察

张弛, 邓文英, 李宁, 许勇飞, 张燕平, 魏辰, 申威, 罗素霞

张弛, 邓文英, 李宁, 许勇飞, 张燕平, 魏辰, 申威, 罗素霞. 恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床观察[J]. 肿瘤防治研究, 2016, 43(1): 54-57. DOI: 10.3971/j.issn.1000-8578.2016.01.012
引用本文: 张弛, 邓文英, 李宁, 许勇飞, 张燕平, 魏辰, 申威, 罗素霞. 恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床观察[J]. 肿瘤防治研究, 2016, 43(1): 54-57. DOI: 10.3971/j.issn.1000-8578.2016.01.012
shu
ZHANG Chi, DENG Wenying, LI Ning, XU Yongfei, ZHANG Yanping, WEI Chen, SHEN Wei, LUO Suxia. Different Administration Ways of Endostar Combined with TP Regimen on Advanced Ovarian Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(1): 54-57. DOI: 10.3971/j.issn.1000-8578.2016.01.012
Citation: ZHANG Chi, DENG Wenying, LI Ning, XU Yongfei, ZHANG Yanping, WEI Chen, SHEN Wei, LUO Suxia. Different Administration Ways of Endostar Combined with TP Regimen on Advanced Ovarian Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(1): 54-57. DOI: 10.3971/j.issn.1000-8578.2016.01.012
shu

恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床观察

  • 450008 郑州，郑州大学附属肿瘤医院肿瘤内科

详细信息
    作者简介:

    张弛（1989-），女，硕士在读，主要从事消化道肿瘤的基础与临床研究

  • 中图分类号: R737.31

Different Administration Ways of Endostar Combined with TP Regimen on Advanced Ovarian Cancer Patients

  • Department of Internal Medicine Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China

摘要

    摘要
  • 摘要: 目的 观察重组人内皮抑素恩度（endostar）持续静脉泵入和静脉滴注两种方式联合TP方案治疗进展期卵巢癌的疗效和不良反应。方法 32例经病理组织学和（或）细胞学证实的进展期卵巢癌患者，随机分为试验组（恩度持续静脉泵+TP方案联合治疗）和对照组（恩度静脉滴注+TP方案联合治疗），每组各16例，比较治疗前、治疗2周期、4周期后肿瘤大小、血清VEGF水平的变化，评价临床疗效和安全性。 结果 2周期后试验组有效率和疾病控制率分别为37.5%和62.5%，对照组分别为25.0%和62.5%，两组差异无统计学意义（P>0.05）。4周期后试验组有效率和疾病控制率分别为50.0%和81.3%，对照组分别为31.3%和75.0%，两组有效率差异无统计学意义（P>0.05）。治疗后试验组血清中VEGF的表达量低于对照组（P<0.05），且4周期后VEGF的表达量显著低于2周期（P<0.01）。试验组心脏不良反应、骨髓抑制发生率低于对照组，差异有统计学意义（P<0.05）。 结论 恩度持续静脉泵入近期疗效较好，并可有效下调晚期卵巢癌血清中VEGF的表达，且不良反应轻微。

     

    Abstract: Objective To observe the efficacy and safety of intravenous infusion and pump of rh-endostatin injection (Endostar) combined with paclitaxel puls cisplatin (TP) regimen on patients with advanced ovarian cancer. Methods Thirty-two patients with advanced ovarian cancer confirmed by histopathology or cytopathology were randomly divided into trial group (intravenous pumping+TP, n=16) and control group (intravenous infusion+TP, n=16). The serum VEGF levels and tumor size were measured before and after two cycles, and after four cycles of treatment between both groups, to evaluate the clinical efficacy and safety. Results After two cycles treatment, the effective rate was 37.5% (6/16) and disease control rate was 62.5% (10/16) in the trail group; while those were 25.0% (4/16) and 62.5% (10/16) in the control group(P>0.05). After four cycles treatment, the effective rate was 50.0% (8/16) and disease control rate was 81.3% (13/16) in the trail group; while those were 31.3% (5/16) and 75.0% (12/16) in the control group(P>0.05). The serum VEGF levels in the trial group were lower than that in the control group (P<0.05), and the VEGF levels after four cycles treatment were significantly lower than that after two cycles treatment (P<0.01). The incidence of cardiovascular toxicity and myelosuppression in the trial group were lower than those in the control group, with significant difference(P<0.05). Conclusion The effect of intravenous pumping of Endostar on patients with advanced ovarian cancer is remarkable; it could reduce the S-VEGF level and has lower adverse reaction than intravenous infusion.

     

    • HTML全文
    • 参考文献(16)
  • [1] Gubbels, JA, Claussen, Kapur AK, et al. The detection, treatment, and biology of epithelial ovarian cancer[J]. J Ovarian Res, 2010, 3: 8.
    [2] Folkman J. Angiogenesis: an organizing principle for drug discovery?[J]. Nat Rev Drug discov, 2007, 6(4): 273-86.
    [3] Ohlund D, Ardnor B, Oman M, et al. Expression pattern and circulating levels of endostatin in patients with pancreas cancer[J]. Int J Cancer, 2008, 122(12): 2805-10.
    [4] Cao DD, Ge W, Wang HM, et al. Efficacy and safety of rhendostain combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a Meta-analysis review[J]. Zhongguo Fei Ai Za Zhi, 2011, 14(5): 404-13. [曹德东, 戈伟, 王慧敏, 等. 重 组人血管内皮抑素联合化疗与单纯化疗在晚期非小细胞肺癌 中疗效比较的系统评价[J]. 中国肺癌杂志, 2011, 14(5): 404-13.]
    [5] Liu AJ, Wei LX, Li YL. The research progess of ovarian cancer molecular targeted therapy[J/CD]. Zhonghua Lin Chuang Yi Shi Za Zhi (Dian Zi Ban), 2011, 5(7): 2008-11. [刘爱军, 韦立新, 李 亚里. 卵巢癌分子靶向治疗的研究进展[J/CD]. 中华临床医师 杂志(电子版), 2011, 5(7): 2008-11.
    [6] Li X, Liu B , Xiao J, et al. Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis and prognosis in colon cancer[J]. J Gastrointest Surg, 2011, 15(11): 2001-10.
    [7] Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer[J]. Anticancer Res, 2004, 24(3b): 19 73-9.
    [8] Penson RT, Dizon DS, Cannistra SA, et al. PhaseⅡstudy of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors[J]. J Clin Oncol, 2010, 28(1): 154-9.
    [9] Aghajanian C. The role of bevacizumab in ovarian cancer-an evolving story[J]. Gynecol Oncol, 2006, 102(2): 131-3.
    [10] Han B, Xiu Q, Wang H, et al. A multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced nonsmall cell lung cancer[J]. J Thoracic Oncol, 2011, 6(6): 1104-9.
    [11] Kisker O, Becker CM, Prox D, et al. Continuous administration of endotatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model[J]. Cancer Res, 2001, 61(20): 7669-74.
    [12] Xin G, Du J, Zhu L, et al. Differential anti-tumor effects for various regimens of endostar plus cisplatin in ovarian cancer[J]. Zhonghua Yi Xue Za Zhi, 2011, 91(47): 3367-70. [辛刚, 杜鹃, 朱 琳, 等. 顺铂与重组人内皮抑素不同联合用药方案对裸鼠卵巢 癌的疗效[J]. 中华医学杂志, 2011, 91(47): 3367-70.]
    [13] Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer[J]. Cancer Control, 2011, 18(1): 31-43.
    [14] Jazaeri AA, Slack-Davis JK. The promise of antiangiogenic therapy for ovarian cancer[J]. Cancer Biol Ther, 2009, 8(23): 2273-4.
    [15] Jiang XD, Dai P, Wu J, et al. The recombinant human endostatin improves the blood perfusion and hypoxia in non-small cell lung cancer[J]. Zhonghua Lao Nian Yi Xue Za Zhi, 2011, 30(9): 73 7-41. [蒋晓东, 戴鹏, 吴瑾, 等. 重组人血管内皮抑素对非小 细胞肺癌患者血流灌注和乏氧改善作用的观察[J]. 中华老年医 学杂志, 2011, 30(9): 737-41.]
    [16] Kubota Y. Tumor angiogenesis and anti-angiogenic therapy[J]. Keio J Med, 2012, 61(2): 47-56．
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1285
  • HTML全文浏览量:  377
  • PDF下载量:  680
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-10-18
  • 修回日期:  2015-11-09
  • 刊出日期:  2016-01-24

目录

摘要
HTML全文
    参考文献(16)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：12193515 今日访问：16557

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭